GlassScriptPhysician profile
Robert L Anderson
NPI 1851559132
$1,666.32
in general payments reported to CMS, 2019-2025
25 companies · $26.49 in 2025
The $26.49 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $637 · 2021: $578 · 2022: $18.46 · 2023: $84.87 · 2024: $61.05 · 2025: $26.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $255.00 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $182.80 | 2019-2021 | |
| Boston Scientific Corporation | $176.61 | 2019-2025 | Exalt Model D |
| Abbott Laboratories | $140.82 | 2019 | |
| Pfizer INC. | $130.56 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $86.35 | 2020-2021 | |
| Abbvie INC. | $78.45 | 2021-2023 | Dalvance |
| Pharmacosmos Therapeutics INC. | $68.67 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.81 | 2020-2021 | |
| Inari Medical, INC. | $60.00 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $43.60 | 2019 | |
| Allergan, INC. | $40.91 | 2020 | |
| Novo Nordisk INC | $38.67 | 2020 | |
| Portola Pharmaceuticals, LLC | $34.90 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.25 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $33.60 | 2021 | |
| Chiesi USA, INC. | $31.92 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $29.31 | 2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.42 | 2021 | |
| Melinta Therapeutics, LLC | $24.37 | 2020 | |
| Biogen, INC. | $24.28 | 2021 | |
| Astellas Pharma US INC | $21.58 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.52 | 2024 | Rebyota |
| Smith+Nephew, INC. | $11.84 | 2021 | |
| Ucb, INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.